治疗抵抗性首发精神病患者的神经认知与NMDAR共激动剂通路:一项3年随访纵向研究
该病例对照3年随访纵向研究纳入697例18至35岁首发精神病患者,按治疗反应与抵抗标准分为应答者、有限应答者和治疗抵抗者,并与114名年龄性别匹配的健康对照比较。治疗抵抗者较应答者在加工速度、注意/警觉、工作记忆、言语学习和视觉学习方面得分更低,并显示D-丝氨酸通路失调。作者认为NMDAR共激动剂通路失调为治疗抵抗性首发精神病认知缺陷提供了潜在分子机制。
要点
- 治疗抵抗者较应答者在加工速度、注意/警觉、工作记忆、言语学习和视觉学习得分更低。
- 有限应答者呈现中间表型。
- 治疗抵抗与有限应答合并组显示D-丝氨酸通路失调。
核心结论
- 治疗抵抗性首发精神病患者存在早期认知损害和持续性功能损害。
- NMDAR共激动剂通路失调为治疗抵抗性首发精神病认知缺陷提供了潜在分子机制。
- 作者认为若研究结果被重复,将为基于反应的病人分层和针对认知改善的临床试验提供机制性生物标志物。
研究设计与样本
- 病例对照3年随访纵向研究,纳入697例18至35岁首发精神病患者,并按治疗反应与抵抗标准算法分为应答者、有限应答者和治疗抵抗者。
- 基线评估采用MATRICS共识认知成套测验,并通过磁共振波谱测定前额叶谷氨酸水平及血浆D-丝氨酸和谷氨酸通路关键标志物。
- 患者与年龄和性别匹配的114名健康对照比较。
主要发现
- 患者平均年龄23岁,27%为女性。
- 治疗抵抗者(n=51)较应答者(n=183)在加工速度、注意/警觉、工作记忆、言语学习和视觉学习方面得分更低。
- 有限应答者(n=59)呈现中间表型。
- 治疗抵抗与有限应答合并组显示D-丝氨酸通路失调,丝氨酸消旋酶和丝氨酸羟甲基转移酶1水平较低,谷氨酸-半胱氨酸转运体3水平较应答者高。
- 仅在应答者中,更好的认知与较高的D-丝氨酸和较低的谷氨酸-半胱氨酸转运体3水平相关,该关联在治疗抵抗组中被破坏。
局限性
- 作者认为若研究结果被重复,将为基于反应的病人分层和针对认知改善的临床试验提供机制性生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aims to determine whether 1) individuals with treatment-resistant schizophrenia display early cognitive impairment compared to treatment-responders and healthy controls and 2) N-methyl-D-aspartate-receptor hypofunction is an underlying mechanism of cognitive deficits in treatment-resistance. In this case‒control 3-year-follow-up longitudinal study, n = 697 patients with first-episode psychosis, aged 18 to 35, were screened for Treatment Response and Resistance in Psychosis criteria through an algorithm that assigns patients to responder, limited-response or treatment-resistant category (respectively resistant to 0, 1 or 2 antipsychotics). Assessments at baseline: MATRICS Consensus Cognitive Battery; N-methyl-D-aspartate-receptor co-agonists biomarkers in brain by MRS (prefrontal glutamate levels) and plasma (D-serine and glutamate pathways key markers). Patients were compared to age- and sex-matched healthy controls (n = 114). Results: patient mean age 23, 27% female. Treatment-resistant (n = 51) showed lower scores than responders (n = 183) in processing speed, attention/vigilance, working memory, verbal learning and visual learning. Limited responders (n = 59) displayed an intermediary phenotype. Treatment-resistant and limited responders were merged in one group for the subsequent D-serine and glutamate pathway analyses. This group showed D-serine pathway dysregulation, with lower levels of the enzymes serine racemase and serine-hydroxymethyltransferase 1, and higher levels of the glutamate-cysteine transporter 3 than in responders. Better cognition was associated with higher D-serine and lower glutamate-cysteine transporter 3 levels only in responders; this association was disrupted in the treatment resistant group. Treatment resistant patients and limited responders displayed early cognitive and persistent functioning impairment. The dysregulation of NMDAR co-agonist pathways provides underlying molecular mechanisms for cognitive deficits in treatment-resistant first-episode psychosis. If replicated, our findings would open ways to mechanistic biomarkers guiding response-based patient stratification and targeting cognitive improvement in clinical trials.
引用
- Camporesi S, Xin L, Golay P, et al. Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. Mol Psychiatry. 2024. PMID: 38849515. doi:10.1038/s41380-024-02631-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。